Literature DB >> 15847255

New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels.

A Gal-Moscovici1, M M Popovtzer.   

Abstract

AIMS: Abnormal mineral metabolism in chronic renal disease is associated with bone disease and extraskeletal calcifications. High turnover, hyperparathyroid bone disease, the most common form of renal osteodystrophy, has been the target for aggressive therapy. More recently, an increasing occurrence of low turnover bone disease has been reported. The present study was undertaken to evaluate the current prevalence of different forms of bone disease in a large population on chronic hemodialysis and its relationship to parathyroid hormone (PTH) levels.
METHODS: Ninety-six chronic hemodialysis patients underwent double tetracycline-labeled bone biopsy. Serum PTH levels were obtained in 52 patients at the time of biopsy. Bone formation rate (BFR/BS) was plotted vs. PTH levels in all patients and in subgroups with PTH ranges between 0-150, 150-500 and 500 - 1,200 pg/ml.
RESULTS: The histomorphometric data showed that 40% of all patients were affected by osteitis fibrosa cystica (OFC). In the remaining 60%, various forms of low-turnover bone disease were observed. There was no correlation between PTH and BFR/BS in all patients (r = 0.28) and in subgroups whose PTH levels ranged between 150 - 500 and 500 - 1,200 pg/ml (r = 0.027, r = 0.21), respectively. A close correlation between PTH and BFR/BS (r = 0.84, p < 0.05) was found only in the subgroup with a PTH level ranging low-turnover bone disease. The predictive between 0 - 150 pg/ml.
CONCLUSIONS: The histomorphometric findings present a wide spectrum of renal osteodystrophy with a shift towardsvalue of PTH is limited as high-turnover osteodystrophy may present with low PTH levels and that with low turnover may occur with high PTH levels. In the latter parathyroidectomy should be avoided. We share the view that bone biopsy remains the "gold standard" diagnostic tool for renal osteodystrophy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15847255     DOI: 10.5414/cnp63284

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  16 in total

Review 1.  Does PTH offer additive value to ALP measurement in assessing CKD-MBD?

Authors:  Edmund J Lamb; Michael P Delaney
Journal:  Perit Dial Int       Date:  2014 Nov-Dec       Impact factor: 1.756

2.  Dysphoria induced in dialysis providers by secondary hyperparathyroidism.

Authors:  Irfana H Soomro; David S Goldfarb
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-16       Impact factor: 8.237

3.  Aluminium and lead abnormalities in children on haemodialysis: relationship with some medications.

Authors:  Manal F Elshamaa; Samar Sabry; Inas Mokhtar; Gamila S El-Saaid; Mona Raafat; Dalia A Abd-El Haleem
Journal:  Arch Med Sci       Date:  2010-06-30       Impact factor: 3.318

Review 4.  Mineral and bone disorders in children with chronic kidney disease.

Authors:  Claus Peter Schmitt; Otto Mehls
Journal:  Nat Rev Nephrol       Date:  2011-09-27       Impact factor: 28.314

5.  Parathyroidectomy for the attainment of NKF-K/DOQI™ and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism.

Authors:  Bojan Kovacevic; Mile Ignjatovic; Vladan Zivaljevic; Vladimir Cuk; Milena Scepanovic; Zaklina Petrovic; Ivan Paunovic
Journal:  Langenbecks Arch Surg       Date:  2012-01-13       Impact factor: 3.445

6.  Chronic kidney disease and bone metabolism.

Authors:  Junichiro James Kazama; Koji Matsuo; Yoshiko Iwasaki; Masafumi Fukagawa
Journal:  J Bone Miner Metab       Date:  2015-02-05       Impact factor: 2.626

7.  Factors associated with calcium requirements after parathyroidectomy in chronic kidney disease patients.

Authors:  Yue Ding; Hongying Wang; Qiang Zou; Yiting Jin; Zijing Zhang; Junwen Huang
Journal:  Int Urol Nephrol       Date:  2017-12-01       Impact factor: 2.370

8.  [Value of serum alkaline phosphatase for predicting 2-year fracture in patients with chronic kidney disease on dialysis].

Authors:  Jianyi Pan; Haitang Hu; Wei Zhang; Jinzhong Chen; Xianrui Dou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-08-30

9.  Achievement of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative: recommended serum calcium, phosphate and parathyroid hormone values with parathyroidectomy in patients with secondary hyperparathyroidism.

Authors:  Woo Young Kim; Jae Bok Lee; Hoon Yub Kim; Sang Uk Woo; Gil Soo Son; Jeoung Won Bae
Journal:  J Korean Surg Soc       Date:  2013-06-26

10.  The role of mast cells in parathyroid bone disease.

Authors:  Russell T Turner; Urszula T Iwaniec; Kevin Marley; Jean D Sibonga
Journal:  J Bone Miner Res       Date:  2010-07       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.